Syndax Pharmaceuticals, Inc. (SNDX) Stock Analysis & Investment Frameworks

Syndax Pharmaceuticals, Inc. (SNDX) stock analysis on Invetso. Review Syndax Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Syndax Pharmaceuticals, Inc. Company Overview

Syndax Pharmaceuticals, Inc. Key Financial Metrics

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Syndax Pharmaceuticals, Inc. Investment Frameworks

Invetso analyzes Syndax Pharmaceuticals, Inc. (SNDX) across the following frameworks:

Explore More SNDX Research